Investment Partners Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$518K Hold
3,273
0.29% 96
2026
Q1
$418K Hold
3,273
0.26% 106
2025
Q4
$399K Buy
3,273
+16
+0.5% +$1.83K 0.25% 109
2025
Q3
$326K Hold
3,257
0.22% 126
2025
Q2
$270K Buy
3,257
+125
+4% +$9.97K 0.19% 129
2025
Q1
$254K Hold
3,132
0.2% 125
2024
Q4
$282K Buy
3,132
+210
+7% +$20.3K 0.22% 117
2024
Q3
$289K Buy
2,922
+31
+1% +$3.05K 0.24% 108
2024
Q2
$268K Hold
2,891
0.24% 107
2024
Q1
$274K Hold
2,891
0.25% 108
2023
Q4
$258K Buy
+2,891
New +$215K 0.26% 107

Other funds holding XBI

Investment Partners Asset Management's XBI Position: Q2 2026 in Review

Investment Partners Asset Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 3,273 shares worth $518K. The position accounts for 0.29% of the portfolio, ranked #96.

Investment Partners Asset Management first reported a position in XBI in Q4 2023 and has held it in 11 quarters since. 368 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Investment Partners Asset Management held 3,273 shares of State Street SPDR S&P Biotech ETF worth $518K as of Q2 2026.
  • Investment Partners Asset Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.29% of Investment Partners Asset Management's portfolio in Q2 2026, its #96 holding.
  • Investment Partners Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 11 quarters since.
  • 368 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Investment Partners Asset Management's 13F filing for Q2 2026, filed 24 Jul 2026.